Journal profile · Pathology
Molecular Medicine Reports
ISSN 1791-2997 · eISSN 1791-3004 · Spandidos Publications · GREECE · Bimonthly · Founded 2008
Molecular Medicine Reports: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 4.91; hybrid open access; median 129 days to acceptance (84 articles, last 24 months); community-reported acceptance: about 66.25%; 359 articles in 2025; indexed in SCIE and Scopus; flagged on an early-warning list or for an indexing change: check before submitting.
Scope
Aims, scope and focus
Molecular Medicine Reports is published by Spandidos Publications and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are MicroRNA in disease regulation, Cancer-related molecular mechanisms research and Circular RNAs in diseases, together about 38.6% of its articles. Its main subfields are Molecular Biology and Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
From the journal's Aims & Scope
Research area (LetPub): Pathology
Editor-in-chief DEMETRIOS A. SPANDIDOSPublisher website
Editorial board by country: none in mainland China; most named Italy 6, Japan 5, Greece 4, Saudi Arabia 3, United Kingdom 2 (26 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology15.8%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology13.3%
- Circular RNAs in diseasesBiochemistry, Genetics and Molecular Biology9.5%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology6.2%
- Autophagy in Disease and TherapyMedicine4.2%
- RNA Research and SplicingBiochemistry, Genetics and Molecular Biology3.9%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology3.2%
- Mesenchymal stem cell researchMedicine3.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 4 |
| Minor | Oncology | Zone 4 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
Early warning / risk: CAS Early Warning Journal List: listed in the 2021 edition (medium risk) and the 2020 edition (medium risk); not listed in the other 4 editions.LetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.91LetPub ·
- Impact factor (publisher)
- 5Publisher website ·
- CiteScore 2026-06
- 7.3LetPub ·
- CiteScore (publisher)
- 7.3Publisher website ·
- SJR 2026-06
- 0.93LetPub ·
- SJR (publisher)
- 0.84Publisher website ·
- SNIP 2026-06
- 0.95LetPub ·
- SNIP (publisher)
- 0.77Publisher website ·
- h-index
- 43LetPub ·
- h-index
- 114OpenAlex ·
- i10-index
- 9,299OpenAlex ·
- 2-year mean citedness
- 5.49OpenAlex ·
- Self-citation rate
- 2%LetPub ·
- Share of gold OA articles
- 93.42%LetPub ·
Volume
- Articles per year
- 281LetPub ·
Articles by year OpenAlex count · 14,126 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 245 | 235 | 1,005 |
| 2025 | 359 | 347 | 1,261 |
| 2024 | 273 | 273 | 2,547 |
| 2023 | 230 | 230 | 2,223 |
| 2022 | 344 | 342 | 4,658 |
| 2021 | 761 | 752 | 13,405 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
129 daysMedian, submission to acceptance · P25–P75 96 days – 186 days
- Acceptance to online
- median 36 days (84 articles)
- Submission to online
- median 174 days
- Sample
- 84 articles with submission and acceptance dates (718 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 1.6 monthsLetPub ·
- Average acceptance (community reports)
- 66.25%LetPub ·
- Peer review
- Single-anonymous peer reviewPublisher website · model-extracted
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
Other charges and waivers (author guidelines)
- Page charges
- EUR 110
- Submission fee
- EUR 550
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–300 words
- Keywords
- 5–10
- Reference style
- Numbered, in order of citation
- Cover letter
- Required
Policy excerpts from the journal's websiteAI use, Conflicts of interest, Data availability, License & copyright, Open access, Self-archiving
- AI use Use of artificial intelligence tools
Authors should disclose the use of artificial intelligence (AI)-assisted tools such as chatGPT in the Declarations section (e.g. ‘Use of artificial intelligence tools - During the preparation of this work, AI tools were used to improve the readability and language of the manuscript or to generate images, and subsequently, the authors revised and edited the content produced by the AI tools as neces…
Source ↗Publisher website ·- Conflicts of interest Competing interests
Authors, reviewers and editors must disclose any competing interests that may exist with respect to the publication of a study. Competing interests are at play if the interpretation and presentation of the data, the conclusions or any other information provided by the authors can be influenced (or may be perceived as such) by their personal or financial relationship with other individuals or organ…
Source ↗Publisher website ·- Data availability Availability of data and materials
For all manuscripts submitted to Spandidos Publications, the authors must make provisions for all materials described in the study, including all relevant raw data, to be freely available to any researchers who may wish to use them for non-commercial purposes, while preserving confidentiality and anonymity. If any conclusions made in the paper depend on a particular, dataset, then this dataset mus…
Source ↗Publisher website ·- License & copyright 3.3.9 Copyright
If a figure or table has been published previously (even if you were the author of the manuscript), copyright permission for re-use of the figure or table will often be required. You must acknowledge the original source and submit written permission from the copyright holder to reproduce the material where necessary. As an author of your manuscript, you are responsible for obtaining permissions to…
Source ↗Publisher website ·- Open access 7. Open access
"Open access" articles published online can be freely accessed at the journal's website by all users. The articles are made immediately available as Open access and appear online at PubMed, PubMed Central and Europe PMC. Articles may be licensed under a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International License, a Creative Commons Attribution-NonCommercial 4.0 Internationa…
Source ↗Publisher website ·- Self-archiving 10. Author self-archiving
Authors are encouraged to submit the final publisher’s version PDF of their manuscript to their institution’s repository 6 months following publication, as well as to their funding body’s archive. A link to the published version on the Spandidos Publications website must be included with full citation details and acknowledgement of the journal as the original source. Authors that have purchased Op…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Spandidos Publications
- Country or region
- GREECE
- Language
- English
- Frequency
- Bimonthly
- Founded
- 2008
- ISSN
- 1791-2997
- Electronic ISSN
- 1791-3004
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Molecular Medicine Reports
What CAS zone is Molecular Medicine Reports in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Medicine Reports is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Medicine Reports?
The latest impact factor listed by LetPub is 4.91; CiteScore 7.3, h-index 114.
How long does peer review take at Molecular Medicine Reports?
Based on the dates recorded on 84 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 129 days (interquartile range 96–186 days); authors report an average review time of about 1.6 months; the community-reported acceptance is “about 66.25%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Molecular Medicine Reports?
According to the journal's author guidelines: Abstract: 150–300 words; Keywords: 5–10; Reference style: Numbered, in order of citation; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Molecular Medicine Reports based?
Of the 26 board members whose country the journal's board page names, none are in mainland China; the countries named most often are Italy (6), Japan (5) and Greece (4). Counted from the institutions listed on the board page; for reference only.
Which databases index Molecular Medicine Reports?
According to LetPub and DOAJ records, Molecular Medicine Reports is indexed in SCIE and Scopus.
Is Molecular Medicine Reports open access, and what is the APC?
Molecular Medicine Reports is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-24). Last updated: .